Published in Infect Immun on September 01, 2002
Interleukin 10- and Fcgamma receptor-deficient mice resolve Leishmania mexicana lesions. Infect Immun (2005) 1.18
Cytokines, signaling pathways, and effector molecules required for the control of Leishmania (Viannia) braziliensis in mice. Infect Immun (2007) 1.09
Molecular characterization, expression, and in vivo analysis of LmexCht1: the chitinase of the human pathogen, Leishmania mexicana. J Biol Chem (2004) 0.99
Activation of PI3K/Akt signaling has a dominant negative effect on IL-12 production by macrophages infected with Leishmania amazonensis promastigotes. Exp Parasitol (2008) 0.98
T helper1/t helper2 cells and resistance/susceptibility to leishmania infection: is this paradigm still relevant? Front Immunol (2012) 0.98
Animal models for the study of leishmaniasis immunology. Rev Inst Med Trop Sao Paulo (2014) 0.86
Pathogen-derived oligosaccharides improve innate immune response to intracellular parasite infection. Am J Pathol (2011) 0.82
Nitric oxide production by Peromyscus yucatanicus (Rodentia) infected with Leishmania (Leishmania) mexicana. Mem Inst Oswaldo Cruz (2013) 0.78
The regulation of immunity to Leishmania major. Annu Rev Immunol (1995) 8.05
Altered immune responses in mice lacking inducible nitric oxide synthase. Nature (1995) 6.20
The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol (1998) 5.50
Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol (1996) 2.76
IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol (1995) 2.72
WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity (2001) 2.49
Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti-Leishmania immunity. J Exp Med (1998) 2.30
Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. Immunity (1996) 2.24
Mice from a genetically resistant background lacking the interferon gamma receptor are susceptible to infection with Leishmania major but mount a polarized T helper cell 1-type CD4+ T cell response. J Exp Med (1995) 2.17
CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity (1996) 2.11
Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity. Immunity (1996) 2.05
The clinical and immunological spectrum of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg (1993) 1.58
IL-4-independent inhibition of IL-12 responsiveness during Leishmania amazonensis infection. J Immunol (2000) 1.54
The biogenesis and properties of the parasitophorous vacuoles that harbour Leishmania in murine macrophages. Trends Microbiol (1998) 1.52
Synergy of IL-12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. J Immunol (2002) 1.48
Mice lacking the TNF receptor p55 fail to resolve lesions caused by infection with Leishmania major, but control parasite replication. J Immunol (1996) 1.45
IL-12 is required to maintain a Th1 response during Leishmania major infection. J Immunol (2000) 1.45
IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-gamma when combined with IL-18. Eur J Immunol (1999) 1.45
Regulation of interleukin-12 production in antigen-presenting cells. Adv Immunol (2001) 1.37
Phagocytosis of Leishmania mexicana amastigotes by macrophages leads to a sustained suppression of IL-12 production. Eur J Immunol (1998) 1.27
Mice defective in Fas are highly susceptible to Leishmania major infection despite elevated IL-12 synthesis, strong Th1 responses, and enhanced nitric oxide production. J Immunol (1998) 1.18
Silent infection of bone marrow-derived dendritic cells by Leishmania mexicana amastigotes. Eur J Immunol (2001) 1.18
Potentiality of interleukin-18 as a useful reagent for treatment and prevention of Leishmania major infection. Infect Immun (2000) 1.13
The resolution of lesions induced by Leishmania major in mice requires a functional Fas (APO-1, CD95) pathway of cytotoxicity. Eur J Immunol (1998) 1.05
SCID mice reconstituted with IL-4-deficient lymphocytes, but not immunocompetent lymphocytes, are resistant to cutaneous leishmaniasis. J Immunol (1997) 0.96
Genetically resistant mice lacking IL-18 gene develop Th1 response and control cutaneous Leishmania major infection. J Immunol (2000) 0.95
BALB/c mice bearing a transgenic IL-12 receptor beta 2 gene exhibit a nonhealing phenotype to Leishmania major infection despite intact IL-12 signaling. J Immunol (2001) 0.93
Susceptibility to Leishmania mexicana infection is due to the inability to produce IL-12 rather than lack of IL-12 responsiveness. Immunol Cell Biol (2001) 0.93
Course of Leishmania infection in beta 2-microglobulin-deficient mice. Immunol Lett (1993) 0.91
The development of a Th1-type response and resistance to Leishmania major infection in the absence of CD40-CD40L costimulation. J Immunol (2001) 0.90
T-cell responses to immunodominant LACK antigen do not play a critical role in determining susceptibility of BALB/c mice to Leishmania mexicana. Infect Immun (2001) 0.89
In vitro indomethacin administration upregulates interleukin-12 production and polarizes the immune response towards a Th1 type in susceptible BALB/c mice infected with Leishmania mexicana. Parasite Immunol (2001) 0.89
Incidence of localized cutaneous leishmaniasis (chiclero's ulcer) in Mexico. Trans R Soc Trop Med Hyg (1990) 0.88
Parasitic load and histopathology of cutaneous lesions, lymph node, spleen, and liver from BALB/c and C57BL/6 mice infected with Leishmania mexicana. Am J Trop Med Hyg (2002) 0.87
IL-12 receptor regulation in IL-12-deficient BALB/c and C57BL/6 mice. Eur J Immunol (2000) 0.85
Maintenance of IL-12-responsive CD4+ T cells during a Th2 response in Leishmania major-infected mice. Eur J Immunol (2000) 0.84
Rapid early onset lymphocyte cell death in mice resistant, but not susceptible to Leishmania major infection. Apoptosis (2000) 0.82
Diffuse cutaneous leishmaniasis in Mexico. Am J Trop Med Hyg (1989) 0.79
Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet (2003) 6.52
Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol (2009) 4.63
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology (2013) 2.70
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut (2011) 2.57
The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med (2002) 2.45
Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol (2003) 2.32
A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes (2002) 2.24
TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab (2011) 2.17
Bacterial c-di-GMP is an immunostimulatory molecule. J Immunol (2007) 2.13
Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc Natl Acad Sci U S A (2007) 2.13
Endogenous IFN-gamma is required for resistance to acute Trypanosoma cruzi infection in mice. J Immunol (1991) 2.08
The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol (2004) 1.96
Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3. Blood (2005) 1.83
Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum (2004) 1.79
Chagas disease in European countries: the challenge of a surveillance system. Euro Surveill (2011) 1.69
1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol (2007) 1.69
Differential migration behavior and chemokine production by myeloid and plasmacytoid dendritic cells. Hum Immunol (2002) 1.62
Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J Immunol (2009) 1.57
Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox. Proc Natl Acad Sci U S A (2004) 1.56
Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs. J Immunol (2002) 1.54
iNOS-producing inflammatory dendritic cells constitute the major infected cell type during the chronic Leishmania major infection phase of C57BL/6 resistant mice. PLoS Pathog (2009) 1.53
Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis. Brain (2005) 1.51
Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood (2003) 1.44
A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. J Immunol (2004) 1.43
MyD88-dependent activation of B220-CD11b+LY-6C+ dendritic cells during Brucella melitensis infection. J Immunol (2007) 1.39
Cutting edge: differential chemokine production by myeloid and plasmacytoid dendritic cells. J Immunol (2002) 1.34
Frequency of the congenital transmission of Trypanosoma cruzi: a systematic review and meta-analysis. BJOG (2013) 1.34
Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. J Clin Invest (2003) 1.32
Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol (2009) 1.32
Lipopolysaccharide-mediated interferon regulatory factor activation involves TBK1-IKKepsilon-dependent Lys(63)-linked polyubiquitination and phosphorylation of TANK/I-TRAF. J Biol Chem (2007) 1.30
Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes (2010) 1.29
Langerhans cell histiocytosis: fascinating dynamics of the dendritic cell-macrophage lineage. Immunol Rev (2010) 1.28
Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol (2004) 1.28
Cutting edge: proangiogenic properties of alternatively activated dendritic cells. J Immunol (2005) 1.25
Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways. J Invest Dermatol (2011) 1.24
Evaluation of the enzyme-linked immunosorbent assay (ELISA) and other serological tests for the diagnosis of toxoplasmosis. Bull World Health Organ (1980) 1.23
Human bladder as a novel target for vitamin D receptor ligands. J Clin Endocrinol Metab (2004) 1.22
CD11c-expressing cells reside in the juxtavascular parenchyma and extend processes into the glia limitans of the mouse nervous system. Acta Neuropathol (2010) 1.21
Circulating immune complexes in schistosomiasis. Immunology (1977) 1.20
Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J Immunol (2002) 1.18
The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am J Physiol Renal Physiol (2009) 1.16
Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J Endocrinol (2011) 1.16
Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J Immunol (2006) 1.16
Myd88-dependent in vivo maturation of splenic dendritic cells induced by Leishmania donovani and other Leishmania species. Infect Immun (2004) 1.14
Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE. J Mol Med (Berl) (2008) 1.14
Unique regulation of CCL18 production by maturing dendritic cells. J Immunol (2003) 1.14
Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J Endocrinol (2012) 1.13
Induction of progressive demyelinating autoimmune encephalomyelitis in common marmoset monkeys using MOG34-56 peptide in incomplete freund adjuvant. J Neuropathol Exp Neurol (2010) 1.13
Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem (2013) 1.13
Suppressive effect of 1alpha,25-dihydroxyvitamin D3 on type I IFN-mediated monocyte differentiation into dendritic cells: impairment of functional activities and chemotaxis. J Immunol (2005) 1.11
Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output. Hepatology (2011) 1.11
IFN-gamma-independent IgG2a production in mice infected with viruses and parasites. Int Immunol (2000) 1.10
TLR4 and Toll-IL-1 receptor domain-containing adapter-inducing IFN-beta, but not MyD88, regulate Escherichia coli-induced dendritic cell maturation and apoptosis in vivo. J Immunol (2005) 1.09
Identification of serum N-acetylmuramoyl-l-alanine amidase as liver peptidoglycan recognition protein 2. Biochim Biophys Acta (2005) 1.09
Proinflammatory bacterial peptidoglycan as a cofactor for the development of central nervous system autoimmune disease. J Immunol (2005) 1.08
In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. J Invest Dermatol (2004) 1.08
Gemini vitamin D analogues inhibit estrogen receptor-positive and estrogen receptor-negative mammary tumorigenesis without hypercalcemic toxicity. Cancer Prev Res (Phila) (2008) 1.08
Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol Pharmacol (2010) 1.08
Growth phase of orally administered Lactobacillus strains differentially affects IgG1/IgG2a ratio for soluble antigens: implications for vaccine development. Vaccine (2003) 1.05
Sensitization to Schistosoma mansoni antigen in uninfected children born to infected mothers. J Infect Dis (1976) 1.05
The endogenous balance of soluble tumor necrosis factor receptors and tumor necrosis factor modulates cachexia and mortality in mice acutely infected with Trypanosoma cruzi. Infect Immun (1999) 1.05
Experimental autoimmune encephalomyelitis in the common marmoset, a bridge between rodent EAE and multiple sclerosis for immunotherapy development. J Neuroimmune Pharmacol (2009) 1.04
Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. Biochim Biophys Acta (2007) 1.04
In situ microscopy analysis reveals local innate immune response developed around Brucella infected cells in resistant and susceptible mice. PLoS Pathog (2012) 1.04
Vitamin D endocrine system and the immune response in rheumatic diseases. Vitam Horm (2011) 1.04
Modelling of multiple sclerosis: lessons learned in a non-human primate. Lancet Neurol (2004) 1.04
Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. Exp Dermatol (2012) 1.04
Animal models of spontaneous autoimmune disease: type 1 diabetes in the nonobese diabetic mouse. Methods Mol Biol (2007) 1.03
IL-12 administration accelerates autoimmune diabetes in both wild-type and IFN-gamma-deficient nonobese diabetic mice, revealing pathogenic and protective effects of IL-12-induced IFN-gamma. J Immunol (2003) 1.03
Crucial role of gamma interferon-producing CD4+ Th1 cells but dispensable function of CD8+ T cell, B cell, Th2, and Th17 responses in the control of Brucella melitensis infection in mice. Infect Immun (2012) 1.02
Trypanosoma cruzi infection in mice induces a polyisotypic hypergammaglobulinaemia and parasite-specific response involving high IgG2a concentrations and highly avid IgG1 antibodies. Parasite Immunol (1994) 1.02
In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology. J Neuroimmunol (2005) 1.02
High levels of myeloid-related protein 14 in human atherosclerotic plaques correlate with the characteristics of rupture-prone lesions. Arterioscler Thromb Vasc Biol (2009) 1.02
The vitamin D receptor as a therapeutic target. Expert Opin Ther Targets (2006) 1.01
Interleukin-6 (IL-6) production in mice infected with Trypanosoma cruzi: effect of its paradoxical increase by anti-IL-6 monoclonal antibody treatment on infection and acute-phase and humoral immune responses. Infect Immun (1994) 1.01
The in and out of monocytes in atherosclerotic plaques: Balancing inflammation through migration. Proc Natl Acad Sci U S A (2004) 1.00
Phagocytes containing a disease-promoting Toll-like receptor/Nod ligand are present in the brain during demyelinating disease in primates. Am J Pathol (2006) 1.00
Inflammation in multiple sclerosis: the good, the bad, and the complex. Lancet Neurol (2002) 0.99
GATA3 expression is decreased in psoriasis and during epidermal regeneration; induction by narrow-band UVB and IL-4. PLoS One (2011) 0.98
Autoimmunity against myelin oligodendrocyte glycoprotein is dispensable for the initiation although essential for the progression of chronic encephalomyelitis in common marmosets. J Neuropathol Exp Neurol (2008) 0.98
Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome. J Steroid Biochem Mol Biol (2012) 0.98
Neuron-interacting satellite glial cells in human trigeminal ganglia have an APC phenotype. J Immunol (2009) 0.98
Unravelling the T-cell-mediated autoimmune attack on CNS myelin in a new primate EAE model induced with MOG34-56 peptide in incomplete adjuvant. Eur J Immunol (2011) 0.98
Comparisons of immunological tests for serodiagnosis of Chagas disease in Bolivian patients. Trop Geogr Med (1985) 0.98
CD40 ligation prevents Trypanosoma cruzi infection through interleukin-12 upregulation. Infect Immun (1999) 0.97
Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease. Immunol Lett (2010) 0.97
Distinct expression profiles of the peripheral cannabinoid receptor in lymphoid tissues depending on receptor activation status. J Immunol (2004) 0.97
Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. Dis Colon Rectum (2004) 0.97
Special attractions for suppressor T cells. Trends Immunol (2003) 0.97
Spontaneous and prostatic steroid binding protein peptide-induced autoimmune prostatitis in the nonobese diabetic mouse. J Immunol (2007) 0.97
Maternal Trypanosoma cruzi infection upregulates capacity of uninfected neonate cells To produce pro- and anti-inflammatory cytokines. Infect Immun (2000) 0.97
The cachexia associated with Trypanosoma cruzi acute infection in mice is attenuated by anti-TNF-alpha, but not by anti-IL-6 or anti-IFN-gamma antibodies. Parasite Immunol (1995) 0.96
Evaluation of circulating antigens by a sandwich radioimmunoassay, and of antibodies and immune complexes, in Schistosoma mansoni-infected African parturients and their newborn children. Am J Trop Med Hyg (1980) 0.96
Decay-accelerating factor (CD55) is expressed by neurons in response to chronic but not acute autoimmune central nervous system inflammation associated with complement activation. J Immunol (2005) 0.96